Chemomab Therapeutics Ltd.
CMMB
$3.40
-$0.0796-2.29%
NASDAQ
| 06/30/2025 | 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.07% | 6.79% | -73.54% | -58.56% | -16.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -39.97% | -16.50% | -54.02% | -55.27% | 70.09% |
| Operating Income | 39.97% | 16.50% | 54.02% | 55.27% | -70.09% |
| Income Before Tax | 43.35% | 13.29% | 54.25% | 55.70% | -71.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 43.35% | 13.29% | 54.44% | 55.81% | -71.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 43.35% | 13.29% | 54.44% | 55.81% | -71.49% |
| EBIT | 39.97% | 16.50% | 54.02% | 55.27% | -70.09% |
| EBITDA | 40.19% | 16.50% | 54.10% | 55.37% | -70.21% |
| EPS Basic | 65.01% | 40.18% | 64.71% | 65.64% | -77.01% |
| Normalized Basic EPS | 65.03% | 40.16% | 64.54% | -- | -76.58% |
| EPS Diluted | 65.01% | 40.18% | 64.71% | 65.64% | -77.01% |
| Normalized Diluted EPS | 65.03% | 40.16% | 64.54% | -- | -76.58% |
| Average Basic Shares Outstanding | 62.02% | 44.90% | 29.05% | 28.58% | -3.11% |
| Average Diluted Shares Outstanding | 62.01% | 44.91% | 29.07% | 28.58% | -3.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |